The medication effect score reflects overall intensity of a diabetes regimen by consolidating dosage and potency of agents used. Little is understood regarding how medication intensity relates to clinical factors. We updated the medication effect score to account for newer agents and explored associations between medication effect score and patient-level clinical factors.
Methods
Cross-sectional analysis of baseline data from a randomized controlled trial involving 263 Veterans with type 2 diabetes and hemoglobin A1c levels ≥8.0% (≥7.5% if under age 50). Medication effect score was calculated for all patients at baseline, alongside additional measures including demographics, comorbid illnesses, hemoglobin A1c, and self-reported psychosocial factors. We used multivariable regression to explore associations between baseline medication effect score and patient-level clinical factors.
Results
Our sample had a mean age of 60.7 (SD = 8.2) years, was 89.4% male, and 57.4% non-White. Older age and younger onset of diabetes were associated with a higher medication effect score, as was higher body mass index. Higher medication effect score was significantly associated with medication nonadherence, although not with hemoglobin A1c, self-reported hypoglycemia, diabetes-related distress, or depression.
Discussion
We observed several expected associations between an updated medication effect score and patient-level clinical factors. These associations support the medication effect score as an appropriate measure of diabetes regimen intensity in clinical and research contexts.
WangCWangXGongG, et al.
Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer2012;
130: 1639–1648.
2.
BaileyCJKodackM.Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract2011;
65: 314–322.
3.
DaileyGKimMSLianJF.Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res2002;
30: 71–79.
4.
DonnellyLAMorrisADEvansJM, et al.
Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM2007;
100: 345–350.
5.
PollackMChastekBWilliamsSA, et al.
Impact of treatment complexity on adherence and glycemic control: an analysis of oral antidiabetic agents. J Clin Outcomes Manag2010;
17: 257–265.
6.
de VriesSTKeersJCVisserR, et al.
Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res2014;
76: 134–138.
7.
IngersollKSCohenJ.The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med2008;
31: 213–224.
8.
EgedeLEGebregziabherMEcholsC, et al.
Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother2014;
48: 562–570.
9.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;
352: 837–853.
10.
DuckworthWAbrairaCMoritzT, et al.
Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med2009;
360: 129–139.
11.
Action to Control Cardiovascular Risk in Diabetes Study Gerstein HC, Miller MEet al.
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008;
358: 2545–2559.
12.
GroupASGersteinHCMillerME, et al.
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med2011;
364: 818–828.
13.
RiddleMCAmbrosiusWTBrillonDJ, et al.
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care2010;
33: 983–990.
14.
MayerSBJeffreysASOlsenMK, et al.
Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. Diabetes Obes Metab2014;
16: 90–93.
15.
Carter ScPMKeoghJB.Effect of intermittent compared with continuous energy restricted diet on glycemic control in patients with type 2 diabetes: a randomized noninferiority trial. JAMA Netw Open2018;
1(3): e180756.
16.
CrowleyMJEdelmanDVoilsCI, et al.
Jump starting shared medical appointments for diabetes with weight management: rationale and design of a randomized controlled trial. Contemp Clin Trials2017;
58: 1–12.
17.
DormanRBSerrotFJMillerCJ, et al.
Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg2012;
255: 287–293.
18.
KempfKAltpeterBBergerJ, et al.
Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Dia Care2017;
40: 863–871.
19.
TayJLuscombe-MarshNDThompsonCH, et al.
A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. Dia Care2014;
37: 2909–2918.
20.
TayJLuscombe-MarshNDThompsonCH, et al.
Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr2015;
102: 780–790.
21.
TayJThompsonCHLuscombe-MarshND, et al.
Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: a 2-year randomized clinical trial. Diabetes Obes Metab2018;
20: 858–871.
22.
WatsonNDyerKBuckleyJ, et al.
Effects of low-fat diets differing in protein and carbohydrate content on cardiometabolic risk factors during weight loss and weight maintenance in obese adults with type 2 diabetes. Nutrients2016;
8(5): E289.
23.
WatsonNADyerKABuckleyJD, et al.
A randomised trial comparing low-fat diets differing in carbohydrate and protein ratio, combined with regular moderate intensity exercise, on glycaemic control, cardiometabolic risk factors, food cravings, cognitive function and psychological wellbeing in adults with type 2 diabetes: Study protocol. Contemp Clin Trials2015;
45: 217–225.
24.
NathanDMBuseJBDavidsonMB, et al.
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2009;
32: 193–203.
25.
DeFronzoRAGoodmanAM.Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med1995;
333: 541–549.
26.
SherifaliDNerenbergKPullenayegumE, et al.
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care2010;
33: 1859–1864.
27.
SimonsonDCKouridesIAFeinglosM, et al. The Glipizide Gastrointestinal Therapeutic System Study Group.Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care1997;
20: 597–606.
28.
WuDLiLLiuC.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab2014;
16: 30–37.
29.
HerzMJohnsDReviriegoJ, et al.
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus. Clin Ther2003;
25: 1074–1095.
30.
EspositoKCozzolinoDBellastellaG, et al.
Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab2011;
13: 594–603.
31.
HtikeZZZaccardiFPapamargaritisDWebbDR, et al.
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab2017;
19: 524–536.
32.
AndreadisPKaragiannisTMalandrisK, et al.
Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab2018;
20: 2255–2263.
33.
ZaccardiFWebbDRHtikeZZ, et al.
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab2016;
18: 783–794.
34.
ZammittNNStreftarisGGibsonGJ, et al.
Modeling the consistency of hypoglycemic symptoms: high variability in diabetes. Diabetes Technol Ther2011;
13: 571–578.
35.
VoilsCIMaciejewskiMLHoyleRH, et al.
Initial validation of a self-report measure of the extent of and reasons for medication nonadherence. Med Care2012;
50: 1013–1019.
36.
SnoekFJPouwerFWelchGW, et al.
Diabetes-related emotional distress in Dutch and U.S. diabetic patients: cross-cultural validity of the problem areas in diabetes scale. Diabetes Care2000;
23: 1305–1309.
37.
KroenkeKSpitzerRLWilliamsJB.The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care2003;
41: 1284–1292.
38.
GrossJLKramerCKLeitaoCB, et al.
Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med2011;
154: 672–679.
39.
PhungOJScholleJMTalwarM, et al.
Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA2010;
303: 1410–1418.
40.
ZammittNNFrierBM.Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care2005;
28: 2948–2961.
41.
DaviesMJGagliardinoJJGrayLJ, et al.
Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review. Diabet Med2013;
30: 512–524.
42.
CookeCELeeHYTongYP, et al.
Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin2010;
26: 231–238.
43.
PeyrotMRubinRRKrugerDF, et al.
Correlates of insulin injection omission. Diabetes Care2010;
33: 240–245.
44.
DelahantyLMGrantRWWittenbergE, et al.
Association of diabetes-related emotional distress with diabetes treatment in primary care patients with Type 2 diabetes. Diabet Med2007;
24: 48–54.
45.
GeorgeJPhunYTBaileyMJ, et al.
Development and validation of the medication regimen complexity index. Ann Pharmacother2004;
38: 1369–1376.
